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Background/aim: COVID-19 patients have a wide spectrum of disease severity. Several biomarkers were evaluated as predictors for
progression towards severe disease. IL-21 is a member of common γ-chain cytokine family and creates some specific effects during
programming and maintenance of antiviral immunity. We aimed to assess IL-21 as a biomarker for diagnosis and outcome prediction
in patients hospitalized with COVID-19.
Materials and methods: Patients with a preliminary diagnosis of COVID-19 and pneumonia other than COVID-19 admitted to a
tertiary care hospital were included consecutively in this comparative study.
Results: The study population consisted of 51 patients with COVID-19 and 11 patients with non-COVID-19 pneumonia. Serum IL-21
concentration was markedly higher, and serum CRP concentration was significantly lower in COVID-19 patients compared to nonCOVID-19 pneumonia patients. Within COVID-19 patients, 10 patients showed radiological and clinical progression. Patients with
clinical worsening had lower lymphocyte count and haemoglobin. In addition to that, deteriorating patients had higher urea, LDH
levels, and elevated concentration of both IL-6 and IL-21. The cut-off value of 106 ng/L for IL-21 has 80.0% sensitivity, %60.9 specificity
for discriminating patients with clinical worsening. Multivariable analysis performed to define risk factors for disease progression
identified IL-6 and IL-21 as independent predictors. Odds ratio for serum IL-6 concentrations ≥ 3.2 pg/mL was 8.07 (95% CI: 1.3747.50, p = 0.04) and odds ratio for serum IL-21 concentrations ≥ 106 ng/L was 6.24 (95% CI: 1.04 – 37.3, p = 0.02).
Conclusion: We identified specific differences in serum IL-21 between COVID-19 and non-COVID-19 pneumonia patients. Serum
IL-21 measurement has promising predictive value for disease progression in COVID-19 patients. High serum IL-6 and IL-21 levels
obtained upon admission are independent risk factors for clinical worsening.
Key words: COVID-19, interleukin 21, prognosis

1. Introduction
Patients with new severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection have different
clinical features and different prognosis [1]. COVID-19
patients have a wide spectrum of disease severity, Wu
et al. reported 14% severe and 5% critical cases within
72314 confirmed patients [2]. Even though most patients
might have a favorable prognosis patient with risk factors
such as old age, underlying hypertension and diabetes,
elevated serum total bilirubin, urea, interleukin (IL)
6, d-dimer or decreased lymphocyte count and CD8+
T cells may develop hypoxemia and progress to acute
respiratory distress syndrome (ARDS) [3]. Several

biomarkers were evaluated as predictors for progression
towards severe disease. Henry et al. defined higher white
blood cell count, lower lymphocyte and platelet count
as predictors for severe disease in their meta-analysis.
In addition, higher inflammatory biomarkers such as
C-reactive protein (CRP), procalcitonin, serum ferritin,
lactate dehydrogenase (LDH), IL-2R, and IL-6 are found
to be associated with severe disease in COVID-19 patients
[4]. Chen et al. demonstrated that, apart from increase
of serum cytokines such as IL-2R, IL-6, IL-10 and tumor
necrosis factor (TNF) α, severe COVID-19 patients had
decreased circulating immune cell subsets such as total T
lymphocytes, CD4+ T cells and CD8+ T cells [5].
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Immunopathogenesis of coronavirus infections is
an exuberant immune response resulting in pulmonary
cell infiltration, vascular permeability increase, and
tissue damage [6]. The primary response is a result of a
direct effect of coronavirus, includes cytokine secretion,
apoptosis, pyroptosis, RAS dysfunction due to angiotensinconverting enzyme-2 (ACE2) downregulation and
shedding [7]. Coronavirus-cell interactions result in
increased production of immune mediators, especially
cytokines secreted by T helper (Th) 17 cells such as IL1, IL-6, IL-8, IL-21, TNF-β, monocyte chemoattractant
protein-1 (MCP-1) [6]. The outcomes of primary response
are pulmonary cell infiltration, increase in vascular
permeability, and lymphopenia [7]. The secondary
response created by virus and antibody complex results
in complement system activation, thus, cellular damage.
Antibody-dependent cell mediated cytotoxicity and
antibody-dependent enhancement are possible cellular
damage mechanisms [7, 8].
IL-21 is a member of common γ-chain cytokine family
and is produced by activated CD4+ T cells, natural killer
(NK) T cells and Th17 cells. IL-21 has effects on both innate
and adaptive immune response. IL-21 activates dendritic
cells, induces NK cells to produce more interferon (IFN)
γ and, therefore, increases cytotoxic activity. IL-21 inhibits
differentiation to Th1 cells and induces CD8+ T cell
proliferation. IL-21 has upregulating effects on CD27 and
CD28 expression; thus, it has control over viral-specific
effector CD8+ T cells [9]. IL-21 also stimulates B cell
proliferation and promotes B cell maturation playing an
important role for long-term immunity [10].
IL-21 creates some specific effects during
programming and maintenance of antiviral immunity.
IL-21 concentration is higher in patients with acute viral
respiratory tract infections compared to healthy controls.
While IL-21 levels show difference between different
respiratory viruses, IL-21 concentration doesn’t show
any relation with clinical parameters such as fever, cough
and myalgia [11]. Studies on chronic hepatitis B infection
suggest IL-21 is a component of antiviral immune response
controlling viral replication and viral clearance [12, 13].
Serum IL-21 levels are found to be correlated with disease
severity and showed changes during disease course in
Hantavirus infected patients [14].
Identifying COVID-19 patients with risk of clinical
worsening is very important to select these cases to
administer appropriate care and treatment. We aimed to
assess IL-21 as a biomarker for diagnosis and outcome
prediction in patients hospitalized with COVID-19.
2. Materials and methods
2.1. Study design and participants
Patients with a preliminary diagnosis of COVID-19
admitted to a tertiary care hospital between 15 May

and 15 June 2020 were included consecutively in this
comparative study. Patients admitted to the department of
pulmonology with a preliminary diagnosis of pneumonia
other than COVID-19 were also included consecutively.
Patients aged younger than 18 years old and patients with
acute hepatitis, congestive heart failure, or lung cancer
were excluded from the study.
2.2. Definitions
COVID-19 is defined as SARS-CoV-2-induced coronavirus
disease. Definition of possible COVID-19 cases according
to national guideline conducted by the Turkish Ministry
of Health has four categories [15]. Proven COVID-19
is patients with positive real-time reverse transcriptasepolymerase chain reaction (RT-PCR) test for SARS-CoV-2.
Patients with respiratory rate >30 per min or oxygen
saturation ≤ 90% or age > 50 years or lymphocyte count
< 800/µL or CRP > 50 mg/L or ferritin > 500ng/mL or
d-dimer > 1000 ng/mL and with bilateral infiltration in
chest computed tomography (CT) are being considered
to be treated in a hospital [15]. Clinical worsening is
described as progression in radiological findings, clinical
parameters and inflammatory markers. Radiological
findings compatible with progression were determined by
chest x-ray and/or chest CT. New ground-glass opacities,
consolidation, crazy-paving sign and/or reverse halo that
weren’t present at the initial examination were considered
as the progression of the disease. Clinical parameters
evaluated for progression consisted of ongoing fever over
37.8 °C, increased respiratory rate and decreased oxygen
saturation compared to initial examination. Increased CRP
and ferritin levels compared to the first result at admission
were measurements of inflammatory response indicating
clinical worsening.
Pneumonia patients were defined as a demonstrable
infiltrate by chest radiograph or other imaging technique in
addition to suggestive clinical symptoms, with or without
microbiological data [16]. Patients with pneumonia were
differentiated from COVID-19 patients by negative RTPCR results and chest CT findings not compatible for
SARS-CoV-2 infection. Patients with pneumonia didn’t
have any contact with COVID-19 patients, suggesting
risk of transmission. Laboratory measurements such
as neutrophil percentage, CRP and procalcitonin were
suggestive of bacterial etiology. Patient classifications
and definition of clinical worsening were done by two
experienced pulmonologists.
The gold standard for diagnosis of COVID-19 is a
positive RT-PCR test for SARS-CoV-2. However, it is
shown that chest CT has higher sensitivity for diagnosis
of RT-PCR test [17, 18]. Typical chest CT patterns and
distributions are carefully described by the Radiological
Society of North America (RSNA) expert consensus
statement. According to RSNA bilateral and peripheral
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distributed ground-glass opacities with or without
consolidation or crazy-paving sign are typical appearances
of early COVID-19 pneumonia. Reverse halo sign or
organizing pneumonia patterns can be seen later in
the disease course [19]. Definitions according to RSNA
are shown to have very good interobserver agreement
among chest radiologists [20]. In our study, chest CT of all
suspected COVID-19 patients were evaluated by a chest
radiologist and two experienced pulmonologists.
2.3. Hospital care and treatment of patients
Clinical decisions such as hospital admission and treatment
were in accordance with national guideline conducted by
the Turkish Ministry of Health [15].
2.4. Data collection
Demographic data, clinical presentation, laboratory tests
and chest CT data were collected from inpatient medical
records by a trained team of pulmonary physicians.
Laboratory data included complete blood count, liver and
renal functions, infection biomarkers, coagulation profile,
LDH, and serum ferritin measured upon admission.
Nasopharyngeal swabs were collected once upon
admission to be tested by RT-PCR. If the patient was
evaluated as high probability for COVID-19 but had
one negative result of RT-PCR, a second nasopharyngeal
swab was performed. The decision for a third respiratory
tract specimen RT-PCR test was decided by the attending
physician. Blood and sputum cultures were taken in order
to detect possible bacterial pathogens.
2.5. IL-6 and IL-21 measurements
Peripheral venous blood (~ 5 mL) was collected from
study participants by venipuncture. Blood samples were
taken once at the time of hospitalization before treatment
procedures. Blood samples were centrifuged at 3000 × g for
15–20 min. Obtained serum samples were stored at –80 °C
until analyzed. Briefly, before starting the assay procedure,
the supernatants and ELISA reagents were brought to
room temperature, and both IL-6 and IL-21 ELISA
assays were performed according to the manufacturer’s
recommendations. Microplates were processed with an
optical microplate reader at 450 nm and 570 nm. The
absorbance at 570 nm was subtracted from the absorbance
at 450 nm. OD values were calculated accordingly by
drawing the standard curve. Serum IL-6 measurement was
done by enzyme-linked immunosorbent assay (ELISA)
for quantitative detection of human IL-6 (Invitrogen,
Ebioscience-Thermo) according to the instructions of
the manufacturer. The assay range for IL-6 was 1.56 100 pg/mL and sensitivity was 0.92 pg/mL. Serum IL-21
measurement was done by ELISA sandwich kit (Bioassay
Technology Laboratory) according to the instructions of
the manufacturer. The assay range for IL-21 was 5ng/L–
1500ng/L, and sensitivity was 2.46 ng/mL.
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2.6. Statistical analysis
Statistical analyses were performed using IBM SPSS
Statistics for Windows, Version 22.0 software program
(IBM Corp., Armonk, NY, USA) and MedCalc
statistical software 2021. Variables were investigated
using histogram and analytical methods (KolmogorovSimirnov/Shapiro-Wilk’s test) to determine distribution.
Continuous data are described as the mean ± standard
deviation or median (interquartile range) if normally
distributed or non-normally distributed, respectively.
Categorical characteristics are described as numbers
(%). Correlation coefficients and their significance were
calculated using the Spearman test. Continuous outcome
variables were compared between groups by two-sample
t-test for normally distributed data and by Mann–Whitney
U-test for nonnormally distributed data. The ability of
serum IL-6 and IL-21 levels to discriminate patients with
clinical worsening was analyzed using receiver operating
characteristics (ROC) curve analysis. Optimal cutoff
maximizing sensitivity and specificity was selected.
Candidate risk factors related with clinical outcome were
evaluated firstly by univariate analysis and then possible
risk factors with p values below 0.15 were evaluated by
logistic regression analysis to determine independent
predictors of patient clinical outcome. Hosmer-Lemeshow
goodness of fit statistics was used to assess model fit. An
overall 5% type-1 error level was used to infer statistical
significance.
2.7. Ethical approval
The study was approved by the ethics committee of the
Uludağ University Faculty of Medicine (date: 29/04/2020
number: 2020-7/25). Written informed consent was
obtained from every participant prior to their inclusion in
the study.
3. Results
3.1. Patient demographics and characteristics of the
study population
A total of 62 patients were included in this study. Study
population consisted 51 (82.2%) patients with COVID-19,
11 (18.8%) patients with non-COVID-19 pneumonia.
Within COVID-19 patients, 25 (49%) patients were
PCR positive, 26 (51%) were diagnosed by clinical and
radiologic features. The mean age was 54.9 ± 16.5 and
29 (46.7%) were male. The symptoms started 3 [2–6]
days before admission, the most common self-reported
symptoms were cough and fever. Frequent comorbidities
were as follows: hypertension, diabetes mellitus and
immunosuppression. Chest CT showed 31 (50%) patients
have bilateral lung involvement. Peripheral distribution
was observed in 55 (88.7%) chest CT with lower lobe
dominance in 50 (80%) patients. The most common
patterns seen on chest CT were ground-glass opacity and
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consolidation. The characteristics and clinical features of
the study subjects are outlined in Table-1.
3.2. Differences between COVID-19 and non-COVID-19
pneumonia patients
The patient’s demographics and characteristics were
similar in terms of age, symptoms upon admission and
comorbidities. COVID-19 patients tended to have less
frequent consolidation and central distribution. Whole
blood count and alanine aminotransferase (ALT), aspartate
aminotransferase (AST), urea, creatinine, d-dimer, LDH
on admission were similar between groups. Serum IL-21
concentrations were markedly higher and serum CRP
concentration were significantly lower in COVID-19
patients compared to non-COVID-19 pneumonia patients.
However, serum IL-6 levels showed no difference between
patient groups (Table 1).
3.3. Risk factors for disease progression
Within COVID-19 patients 10 (19.6%) patients showed
radiological and clinical progression. Clinical worsening
was observed on the 6th [3–8] day. Immunocompromised
patients made up half of the deteriorating patients however
other coexisting conditions showed no difference between
patients. Patients with clinical worsening had lower
lymphocyte count and haemoglobin. In addition to that,
deteriorating patients had higher urea and LDH levels.
Elevated concentrations of both IL-6 and IL-21 were
observed in patients with clinical worsening (Table 2).
In order to identify the optimum serum IL-21
concentration threshold which would discriminate
patients with clinical worsening from those who didn’t
show deterioration, a ROC curve analysis was performed.
Area under curve (AUC) for IL-21 was 0.713 [0.523
–0.904] and represented fair discrimination. Cut-off value
of 106 ng/L for IL-21 has 80.0 [44.3–97.4] % sensitivity,
60.9 [44.5–75.8] % specificity, 33.3 [24.4–.45.0] %
positive predictive value and 92.5 [77.9 -.97.7] % negative
predictive value. Positive likelihood ratio is calculated to
be 2.05. A separate ROC curve analysis was performed
to evaluate the diagnostic value of serum IL-6 levels in
distinguishing deteriorating patients from patients who
didn’t show disease progression. Discrimination of IL-6
was fair with AUC 0.726 [0.533–0.918]. Calculated cutoff value for serum IL-6 concentration 3.24 pg/mL has 80
[44.3–97.4] % sensitivity, 51.2 [35.1–67.1] % specificity,
28.5 [20.4–38.3] % positive predictive value and 91.3
[74.5–97.4] % negative predictive value with 1.64 positive
likelihood ratio. Youden index for IL-21 and IL-6 were
0.434 and 0.431, respectively. Pairwise comparison of ROC
curves showed no difference between serum IL-21 and
serum IL-6 levels in discriminating patients with disease
progression (p = 0.93) (Figure).
Multivariable analysis performed to define risk
factors for disease progression identified IL-6 and IL-21

as independent predictors. Odds ratio for serum IL-6
concentrations ≥ 3.2 pg/mL was 8.07 (95% CI: 1.37–47.53,
p = 0.04) and odds ratio for serum IL-21 concentrations ≥
106 ng/L was 6.24 (95% CI: 1.04–37.35, p = 0.02). (Table 3)
3.4. Clinical and laboratory correlations with IL-21 and
IL-6
Serum IL-21 level was weakly negatively correlated with
blood neutrophil count (r = – 0.310, p= 0.02) while serum
IL-6 level was moderately correlated with lymphocyte
count (r = –0.404, p = 0.003), troponin (r = 0.429, p =
0.003) and weakly correlated with CRP (r = 0.298 p =
0.03), procalcitonin (r = 0.343, p = 0.02), d-dimer (r =
0.353, p = 0.02).
Patients who had fever at day 3 after admission had
higher serum IL-21 concentration (409.2 [107.3–658.6]
ng/L vs 101.0 [90.4–150.5] ng/L, p = 0.01). Serum IL-6
measurement was correlated with hospital length of stay
(r = 0.310, p = 0.02).
4. Discussion
Over-activation of T cells, increased T helper 17 (Th17),
and CD8 T cell activity can play a role in immune injury
in severe COVID-19 patients [21]. Clinical findings and
studies about inflammatory biomarkers showed that
exuberant inflammatory responses result in uncontrolled
pulmonary inflammation thus leading to mortality [22].
IL-21 plays critical roles in both cytotoxic and humoral
arms of the immune response. IL-21 and TGF-β are
responsible for the differentiation of naïve CD4+ T cells
to TH17 cells. TH17 cells, in turn, produce IL-21, IL22, IL-17A, IL-17F and CCL20 targeting immune cells,
fibroblasts, endothelial and epithelial cells. These TH17
derived cytokines play a role in the pathogenesis of
many autoimmune, allergic and inflammatory diseases
[23]. IL-21 is also important for the generation and
maintenance of germinal center, differentiation of B cells
and immunoglobulin (Ig) especially IgG1 production
[24, 25]. In addition, IL-21 increases the proliferation and
cytotoxicity of CD8+ T cells [26].
Serum IL-21 and CRP measurements were significantly
different between COVID-19 and non-COVID-19
pneumonia patients. Previous studies evaluated cytokine
levels in different pneumonia groups. IL-6, IL-10, IL-17A
and IFN-γ showed significant differences between viral
community-acquired pneumonia (CAP), pneumococcal
CAP and combined viral-bacterial CAP groups, and
the study created a cytokine-based prediction model.
However, serum IL-21 levels were not detectable in
all samples thus couldn’t be evaluated [27]. In a study
evaluating 76 patients with pneumonia caused by different
respiratory viruses showed patients infected with influenza
A had higher serum IL-21 levels than patients infected
with respiratory syncytial virus [11]. Lieberman et al.

2277

ACET ÖZTÜRK et al. / Turk J Med Sci
Table 1. Demographics, characteristics and initial laboratory measures of COVID-19 patients and pneumonia patients.
Study population
(n = 62)

COVID-19 patients
(n = 51)

Pneumonia patients
(n = 11)

p

Age, years

54.9 ± 16.5

54.3 ± 15.2

57.5 ± 22.3

0.56

Male sex, n(%)

29 (46.7)

27 (52.9)

7 (63.6)

0.41

Fever, n(%)

28 (45.2)

23 (45.1)

5 (45.4)

0.61

Cough, n(%)

39 (62.9)

33 (64.7)

6 (54.5)

0.38

Dyspnea, n(%)

21 (33.9)

18 (35.3)

3 (27.2)

0.44

Sputum production, n(%)

17 (27.4)

14 (27.5)

3 (27.2)

0.65

Fatigue, n(%)

14 (22.6)

13 (25.5)

1 (9.1)

0.22

3 [2–6]

3 [2–6]

2 [1–4]

0.31

Hypertension, n(%)

21 (33.9)

16 (31.4)

5 (45.4)

0.28

Diabetes mellitus, n(%)

17 (27.4)

15 (29.4)

2 (18.1)

0.36

Immunosuppression, n(%)

13 (21)

11 (21.6)

2 (18.1)

0.62

Cancer, n(%)

11 (17.7)

9 (17.6)

0 (0)

0.15

COPD, n(%)

6 (9.7)

5 (9.8)

1 (9.1)

0.71

Asthma, n(%)

5 (8.1)

4 (7.8)

1 (9.1)

0.63

Chronic kidney disease, n(%)

6 (9.7)

4 (7.8)

2 (18.1)

0.28

Transplant recipient

2 (3.2)

2 (3.9)

0 (0)

0.67

31 (50)

27 (52.9)

4 (36.3)

0.97

Upper lobe, n(%)

26 (41.9)

22 (43.1)

4 (36.3)

0.45

Lower lob, n(%)

50 (80)

40 (78.4)

10 (90.9)

0.36

Peripheral, n(%)

55 (88.7)

44 (86.3)

11 (100)

0.28

Central, n(%)

15 (24.2)

10 (19.6)

5 (45.5)

0.08

Ground glass opacity

53 (85.5)

43 (84.3)

10 (90.9)

0.55

Air bronchogram

10 (16.1)

7 (13.7)

3 (27.2)

0.25

Consolidation

19 (30.6)

13 (25.5)

6 (54.5)

0.07

Crazy paving

3 (4.8)

3 (5.9)

0 (0)

0.54

Reticular pattern

5 (8.1)

4 (7.8)

1 (9.1)

0.64

Leukocyte count, K/µL

8.59 [5.94–10.71]

8.06 [5.60–1.06]

9.09 [8.51–12.52]

0.11

Lymphocyte count, K/µL

1.59 [1.052.23]

1.57 [1.00–2.48]

1.66 [0.79–2.07]

0.80

Neutrophil count, K/µL

5.67 [3.02-8.11]

4.83 [3.02–8.05]

6.07 [5.37–11.37]

0.22

Haemoglobin, g/dL

12.3 ± 2.6

12.4 ± 2.73

12.08 ± 2.17

0.57

CRP, mg/L

9.6 [2.5–42.6]

6.2 [2.0–25.4]

20.6 [9.3–95.9]

0.01

Procalcitonin, µg/L

0.05 [0.02-0.15]

0.04 [0.02–0.16]

0.06 [0.03–0.75]

0.42

LDH, U/L

211 [168–303]

211 [178-309]

137 [34–240]

0.55

Ferritin, µg/L

135 [47.3–420.2]

147.0 [50.4–695.6]

69.5 [27.7–307.1]

0.34

d-dimer, mg/L

0.72 [0.31–1.48]

0.66 [0.3–1.5]

1.01 [0.69–1.31]

0.45

Urea, mg/dL

31 [24–42]

29.5 [23.0–39.5]

42 [30.5–52.5]

0.11

Symtoms upon admisson, n(%)

Duration of symptoms before admission, days
Coexisting conditions

Distribution of Chest CT abnormalities
Bilateral involvement of Chest CT, n(%)

Patterns on Chest CT, n(%)

Laboratory measures at admission
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Table 1. (Continued).
Creatinine, mg/dL

0.81 [0.7–1.06]

0.81 [0.68–1.07]

0.79 [0.75–0.94]

0.25

ALT, U/L

19 [11–32]

19.0 [14.2–31.7]

10 [8.5–28.5]

0.18

AST U/L

21 [16–31]

21.0 [16.0–32.2]

19 [14–24]

0.25

IL-6, pg/mL

3.52 [2.95–4.57]

3.45 [2.93–4.31]

3.80 [3.07–5.61]

0.17

IL-21, ng/L

100.9 [90.2–169.0]

105.0 [93.9–210.7]

92.0 [47.6–100.8]

0.01

Length of stay, days

7 [6–9]

7 [6–10]

6 [5–7]

0.01

Notes: Data are mean ± standard deviation or median (IQR 25-75), as appropriate. Abbreviations: CT, computed tomography; CRP,
C-reactive protein; LDH, lactate dehydrogenase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; IL-6, interleukin 6;
IL-21, interleukin 21.

concluded serum IL-1 beta and IL-6 levels can be used to
differentiate S. pneumoniae-CAP and M. pneumoniaeCAP during the acute phase [28]. Similarly in a study
including 201 pneumonia patients showed that serum IL1RA and IL-6 measurements upon admission were higher
in patients with pneumococcal pneumonia [29]. However,
in our study IL-6 levels showed no difference between
COVID-19 and non-COVID-19 pneumonia patients.
In our study lymphopenia, anemia, higher LDH,
urea, IL-6 and IL-21 levels are observed in patients with
clinical worsening. Other studies evaluating prognostic
factors also associated increased serum d-dimer, CRP,
IL-6, procalcitonin, ferritin, troponin, creatine kinase
measurements with worse clinical outcomes [30].
Serum IL-6 concentrations are significantly related with
complicated disease (ARDS, requiring ICU or severe/
critical presentation) and mortality [31].
Cytokine storm is a result of high virus titers and
dysregulation of cytokine/chemokine response which
results in pathological changes of the lung [22]. Cytokines
secreted by Th17 cells are increased in viral infections.
In our study, serum IL-21 and serum IL-6 levels are
independent predictors of clinical worsening. There are few
studies evaluating IL-21 in COVID-19 patients. A study
evaluating adaptive immune response with plasmablasts
from patients with severe COVID-19 requiring ICU
revealed that in early stages of severe disease switch
instruction of B cells are dominated by IL-21 and TGF-β
thus leading to expression of IgG1 and IgA1. Severely
affected COVID-19 patients have significant populations
of CD4+ T cells programmed to express IL-21 and
TGF-β. Despite increased secretion of IgA from B cells,
interestingly this created IgA doesn’t bind SARS-CoV-2
spike or nucleocapsid protein. In addition to that beyond
day 7, patients showed a continued immune reaction
with IL-2/IL-21 activated B cells. These results lead to
the conclusion of the importance of IL-21 and TGF-β
in adaptive and chronic immune reactions not targeting
the SARS-CoV-2 virus itself [32]. Results of high levels

of IL-21 in severe COVID-19 patients are in accordance
with the results of our study. Results of a clinical trial
with IL-15 therapy for COVID-19 [33] and prior studies
indicating IL-21 promoting effects of IL-15 lead to a
conclusion that particularly in patients with diminished B
and/or CD8+ T cell counts treatment with IL-15 and IL21 might be effective [34]. More studies evaluating IL-21
and IL-6 in different viral infections are present. Studies
with chronic hepatitis B infections suggested that IL-21
is a component of antiviral immune response controlling
viral replication and viral clearance [12], and low serum
levels of IL-21 might have a role in the persistence of viral
infections [13]. Chen et al. showed higher serum IL-21
levels are related with disease progression and disease
severity in hemorrhagic fever with renal syndrome caused
by Hantavirus infection [14]. In a study conducted by
Almansa et al. patients with severe respiratory disease
due to pandemic influenza had higher viral load and
higher cytokines such as IL-6, IL-8, IL-10, IL-1ra upon
admission indicating exuberant cytokine response. Within
this study cytokine levels were correlated with viral load
[35]. Serum IL-6 measurements in pandemic H1N1
influenza pneumonia patients predicted worse clinical
parameters such as fever, tachypnea, deoxygenation and
ICU admission [36].
In our study serum IL-6 level is also positively correlated
with length of hospital stay. Lee et al. also defined serum
IL-6 to be correlated with length of stay in pandemic
influenza patients [17]. Serum IL-21 concentration is
found to be higher in patients who had fever at day 3
during the illness course. However, Antalis et al. didn’t
show any relation of serum IL-21 with clinical parameters
such as fever, cough and myalgia within patients infected
with various respiratory viruses other than SARS-CoV-2
[11].
Cytokine measurements and understanding particular
roles of cytokines in COVID-19 disease might help
clinicians to identify patients at risk for worse outcomes
and elucidate potential treatment modalities.
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Table 2. Demographics, characteristics and initial laboratory measures of COVID-19 patients with different clinical course.
Stable patients
(n = 41)

Patients with clinical
worsening (n = 10)

p

Age, years

54.0 ± 16.7

53.4 ± 5.0

0.92

Male sex, n(%)

23 (56)

4 (40)

0.67

Fever, n(%)

20 (48.7)

3 (30)

0.23

Cough, n(%)

26 (63.4)

7 (70)

0.50

Dyspnea, n(%)

15 (36.5)

3 (30)

0.50

Sputum production, n(%)

11 (26.8)

3 (30)

0.56

Fatigue, n(%)

10 (24.3)

3 (30)

0.49

3 [2-5.5]

3 [1.5–7]

0.80

Hypertension, n(%)

12 (29.2)

4 (40)

0.38

Diabetes mellitus, n(%)

11 (26.8)

4 (40)

0.32

Immunosuppression, n(%)

6 (14.6)

5 (50)

0.03

Cancer, n(%)

8 (19.5)

3 (30)

0.23

COPD, n(%)

4 (9.75)

4 (40)

0.68

Asthma, n(%)

4 (9.75)

0 (0)

0.40

Chronic kidney disease, n(%)

2 (4.87)

2 (20)

0.16

Symptoms upon admission, n(%)

Duration of symptoms before admission, days
Coexisting conditions

Distribution of CT abnormalities
Bilateral involvement of Chest CT, n(%)

23 (56.0)

4 (40)

0.73

Upper lobe, n(%)

18 (43.9)

4 (40)

0.53

Lower lob, n(%)

32 (78)

8 (80)

0.65

Peripheral, n(%)

35 (85.3)

9 (90)

0.65

Ground glass opacity

34 (82.9)

9 (90)

0.57

Air bronchogram

4 (9.75)

3 (30)

0.13

Consolidation

9 (21.9)

4 (40)

0.22

Crazy paving

3 (7.3)

0 (0)

0.50

Reticular pattern

3 (7.3)

1 (10)

0.60

Leukocyte count, K/µL

8.29 [6.22–10.9]

6.73 [5.03–9.65]

0.21

Lymphocyte count, K/µL

1.65 [1.32–2.50]

0.78 [0.58–2.27]

0.05

Neutrophil count, K/µL

5.26 [3.29–7.84]

4.17 [2.67–8.35]

0.55

Haemoglobin, g/dL

12.6 ± 2.9

11.4 ± 1.9

0.09

CRP, mg/L

4.9 [2.0–17.0]

18.5 [5.0–213.1]

0.31

Procalcitonin, µg/L

0.03 [0.02–0.13]

0.12 [0.03–0.33]

0.10

LDH, U/L

203.0 [154.0–245.7]

321.5 [231.0–407.5]

0.08

Ferritin, µg/L

147 [50.4–695.6]

183.5 [61.7–1559.2]

0.76

d–dimer, mg/L

0.64 [0.29–1.44]

0.87 [0.57–1.88]

0.33

Urea, mg/dL

29 [23–36]

37 [28–50]

0.06

Creatinine, mg/dL

0.82 [0.70–1.06]

0.69 [0.65–1.28]

0.37

ALT, U/L

19 [15–34]

19 [12.5–21]

0.21

Patterns on Chest CT, n(%)

Laboratory measures at admission
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Table 2. (Continued).
AST U/L

21 [16–35]

20 [13.5–30]

0.49

IL-6, pg/mL

3.17 [2.89–3.91]

4.40 [3.21–20.0]

0.02

IL-21, ng/L

101.0 [89.9–161.6]

295.9 [103.8–611.0]

0.03

Length of stay, days

7 [6–9]

9.5 [9–11]

In hospital mortality, n(%)

1 (2.43)

2 (20)

0.006
0.09

Outcome

Notes: Data are mean ± standard deviation or median (IQR 25–75), as appropriate. Abbreviations: CT, computed
tomography; CRP, C-reactive protein; LDH, lactate dehydrogenase; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; IL-6, interleukin 6; IL-21, interleukin 21.

Figure. Receiver operator characteristic curve for serum IL21 and serum IL-6 discriminating stable patients and patients
with disease progression within the COVID-19 population.

5. Limitations
This study has some limitations. First, patients were
not tested for other respiratory viruses. As shown in
recent studies, other viruses might affect serum IL21 measurements. However, patients admitted within
influenza season were treated with oseltamivir empirically.
Therefore, clinical worsening attributed to undetected
influenza is less likely. Secondly, this study population has
few numbers of patients with non-COVID-19 pneumonia.
This limits the power of statistical analysis such as the
predictive value of biomarkers because they are affected
by prevalence. Thirdly, within COVID-19 patients some
patients are RT-PCR negative. However, chest CT findings
are found to be more sensitive for COVID-19 diagnosis
compared to RT-PCR results [17-18]. Inter-observer
agreement for diagnosis by chest CT is found to be almost

perfect [20], and, in our study, chest CTs of suspected
COVID-19 patients were evaluated by a chest radiologist
and two experienced pulmonologists. In addition to that,
false negative rate of RT-PCR test ranges from 2% to 54% in
different studies [37]. RT-PCR test results are also affected
by time since exposure and time since symptom onset [38,
39]. Pooled analysis performed by Kucirka et al. revealed
38% false negative on the day of symptom onset, 20%
false negative on the 3rd day and increased false negative
results after the 4th day [38]. Our study population was
tested 3 [2 - 7] days after symptom onset. Therefore, taken
into consideration the radiological, clinical and laboratory
parameters, RT-PCR negative COVID-19 patients were
included in the study population. Results from statistical
analysis repeated for only RT-PCR positive patients
showed no difference in terms of difference of serum IL-21
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Table 3. Multivariable analysis of possible risk factors for clinical worsening in COVID-19 patients.
OR

95% CI

p-value

OR

95% CI

p-value

Age, years

1.01

0.96–1.06

0.63

Sex, male

1.83

0.44–7.51

0.40

DM

1.81

0.43–7.68

0.41

HT

1.61

0.38–6.75

0.51

Immunosuppression

5.66

1.24–25.73

0.02

2.35

0.25–16.99

0.40

Smoking

1.77

0.13–23.39

0.66

Bilateral involvement in Chest CT

3.18

0.30–33.25

0.33

Lymphocyte count

0.99

0.99–1.00

0.11

1

0.99–1.00

0.93

Haemoglobulin

0.85

0.65–1.10

0.21

Urea

1.00

0.98–1.01

0.78

LDH

1.00

0.99–1.01

0.26

Ferritin

1.00

0.99–1.00

0.52

CRP

1.05

0.99–1.01

0.31

Procalcitonin

3.79

0.56–25.2

0.16

IL-6 ≥ 3.2 pg/mL

4.20

0.79–22.2

IL-21 ≥ 106 ng/L

6.25

1.17–33.2

0.09

8.07

1.37–47.53

0.04

0.03

6.24

1.04–37.35

0.02

Abbreviations: HT, Hypertension; DM, Diabetes mellitus; IL-6, interleukin 6; IL-21, interleukin 21.

measurements between stable patients and patients with
clinical worsening (Table-S1).
6. Conclusion
We identified specific differences in serum IL-21 between
COVID-19 and non-COVID-19 pneumonia patients.
Serum Il-21 measurement has promising predictive value
for disease progression in COVID-19 patients with 80.0%
sensitivity, 60.9% specificity, and 92.5% negative predictive
value. High serum IL-6 and IL-21 levels obtained upon
admission in COVID-19 patients are risk factors for
clinical worsening independent of lymphocyte count and
immunosuppression. These findings joined with previous
studies support the need for further research on the role
of IL-21 in disease progression and possible treatment
modalities related to IL-21 in COVID-19 patients.
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Table S1. Demographics, characteristics and initial laboratory measures of COVID-19 patients.
Stable Patients
(n = 19)

Patients with clinical
worsening (n = 7)

p

Age

48.9 ± 15.7

58.0 ± 11.0

0.17

Male sex, n(%)

9 (47.3)

1 (14.2)

0.23

Fever, n(%)

10 (52.6)

3 (42.8)

0.67

Cough, n(%)

12 (70.5)

5 (71.4)

1

Dyspnea, n(%)

7 (36.8)

2 (28.5)

1

Sputum production, n(%)

2 (10.5)

3 (42.8)

0.11

Fatigue, n(%)

5 (26.3)

3 (42.8)

0.64

Hypertension, n(%)

4 (21.0)

3 (42.8)

0.35

Diabetes mellitus, n(%)

4 (21.0)

4 (57.1)

0.15

Immunosuppression, n(%)

1 (5.2)

2 (28.5)

0.19

Cancer, n(%)

1 (5.2)

1 (14.2)

0.49

COPD, n(%)

1 (5.2)

0 (0.0)

1

Asthma, n(%)

2 (10.5)

0 (0.0)

1

Chronic kidney disease, n(%)

0 (0.0)

2 (28.5)

0.07

Symptoms upon admission, n(%)

Duration of symptoms before admission, days
Coexisting conditions

Distribution of CT abnormalities
Bilateral involvement of Chest CT

11 (57.8)

3 (42.8)

0.90

Upper lobe

7 (36.8)

3 (42.8)

1.00

Lower lob

11 (57.8)

5 (71.4)

1.00

Peripheral

12 (70.5)

6 (85.7)

0.62

Ground glass opacity

12 (70.5)

6 (85.7)

0.62

Air bronchogram

2 (10.5)

2 (28.5)

0.55

Consolidation

4 (21.0)

3 (42.8)

0.35

Crazy paving

2 (10.5)

0 (0.0)

1.00

Reticular pattern

1 (5.2)

1 (14.2)

0.49

Leukocyte count, K/µL

6.81 [4.76–8.66]

6.35 [5.65–9.00]

0.95

Lymphocyte count, K/µL

1.76 [1.08–2.48]

1.35 [0.78–2.55]

0.73

Neutrophil count, K/µL

4.21 [2.61–5.70]

4.05 [2.54–7.99]

0.95

Haemoglobin, g/dL

13.0 ± 2.4

10.9 ±1.4

0.02

CRP, mg/L

9.4 [2.5–31.4]

18.5 [3.0–33.0]

0.57

Procalsitonin, µg/L

0.03 [0.02–0.10]

0.20 [0.02–1.01]

0.19

LDH, U/L

245.0 [178.0–403.0]

321.5 [231.0–407.5]

0.35

Ferritin, µg/L

158.6 [39.4–474.5]

130 [84.5–183.5]

0.55

d–dimer, mg/L

0.38 [0.25–1.23]

1.22 [0.34–10.2]

0.32

Urea, mg/dL

25.0 [19.2–36.0]

33.5 [27.0–37.7]

0.07

Creatinine, mg/dL

0.7 [0.6–1.0]

0.6 [0.6–0.9]

0.73

ALT, U/L

21.0 [18.0–43.7]

20.5 [16.2–73.5]

0.13

Patterns on Chest CT

Laboratory measures at admission
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AST U/L

23.0 [17.2–45.5]

27.0 [20.0–34.7]

0.69

IL-6, pg/mL

3.46 [3.04–3.95]

2.91 [2.87–3.11]

0.18

IL-21, ng/L

128.3 [84.8–429.3]

602.8 [326.9–619.2]

0.04

Length of stay, days

7.0 [6.0–10.0]

10.0 [9.0–13.0]

0.02

In hospital mortality, n(%)

0 (0.0)

2 (28.5)

0.07

Outcome

Notes: Data are mean ± standard deviation or median (IQR 25-75), as appropriate. Abbreviations: CT, computed
tomography; CRP, C-reactive protein; LDH, lactate dehydrogenase; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; IL-6, interleukin 6; IL-21, interleukin 21.
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